As part of a clinical study, the Early Clinical Trial Unit (ECTU) at NCT/UCC Dresden tested the cancer immunotherapy IMA401 for the first time in patients with advanced solid tumors. IMA401 is a ...

Funding to advance proprietary T-cell engager platforms and pipeline of highly differentiated T-cell engager therapies targeting solid tumors and autoimmune diseases Financing co-led by multiple ...

– Clinical Entry of Lead Program, Targeting LY6G6D, Demonstrates Cartography’s Platform-Driven Oncology Strategy and Potential for First-and-Best-in-Class Targeting Approaches– – Milestone Marks ...

Shares of Cullinan Therapeutics (CGEM) have risen by 31% year-to-date, yet are down 70% over the past five years. I decided to accumulate a position in the company in late December, taking advantage ...

Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China rights to Zelgen’s lead oncology asset, alveltamig (ZG-006), a trispecific ...

Effective marketing for freelancers hinges on a consistent presence in the right places, not scattered efforts across platforms. Freelancers must offer clarity in their positioning to command higher ...

When implemented well, clear boundaries increase trust, professionalism and client satisfaction. Before you set boundaries, identify the small places where you feel frustrated or overwhelmed. Then, ...

Client advisory services (CAS) is the fastest-growing service area for CPA firms, and the rewards can be great. The median growth rate for CAS services was 17% in 2024, and CAS-related revenue is ...

My name means listener. I often ponder if my behavior validates my moniker. I’d like to believe that one day I’ll master the craft of listening. When a client makes a suggestion that seems ...